Antibody Drug Compound Helps Treat Breast Cancer Patients
Women with metastatic HER2-positive breast cancer resistant to standard therapies can experience halted growth of their tumors with a new drug combination, according to early data from a clinical trial led by a researcher from the Dana-Faber Cancer Institute.
